FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133031> ?p ?o ?g. }

• W4308133031 endingPage "A83" @default.
• W4308133031 startingPage "A82" @default.
• W4308133031 abstract "Abstract Background More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. Thus, the drug is potentially useful in the medical treatment of steroid-secreting tumors. The aim of this study was to assess the activity of AA to control cortisol excess in patients with advanced ACC and overt Cushing syndrome. Methods We designed the phase II trial ABACUS (NCT 03145285) whose primary endpoint was normalization of 24-h urinary free cortisol (UFC) excretion within 1 month from treatment start. Inclusion criteria were histologically proven ACC, locally advanced or metastatic disease, and Cushing syndrome confirmed by two 24-h UFC &gt;1.5 times the upper normal limit with suppressed ACTH. No concomitant treatment with mitotane or chemotherapy was allowed for the first 4 weeks of the study. AA was given orally at the daily dose of 1000 mg. Results From 2017 to 2019, we included 17 patients with ACC (2 stage III, 15 stage IV), 13 women (76%), median age 51 years (18-76), of whom 8 have been heavily pretreated and 9 were treatment naïve. In 8 patients, multiple steroid secretion was found. Patients were treated with AA for a median of 17 days (7-163). Median 24-h UFC (measured by gas-mass spectrometry) was 368 μg/24h (121-7422) at baseline and 94 μg/24h (20-1793) at end of treatment (p=0.01). Normalization of 24-h UFC was attained in 8 patients (53%) and a &gt;50% decrement in 11 patients (73%). The median time to effect was 21 days and median 24-h UFC reduction 81.8% (-97.7 - +25.9). Androgen and precursor steroids were also significantly reduced by AA treatment. The median Cushing Syndrome Score was 5.0 (2 - 8) at baseline and 3.5 (1 - 6) at the end of treatment, thus confirming clinical improvement. Blood pressure was significantly reduced and hypokalemia was not observed. In 2 patients, treatment was discontinued for toxicity. Seven patients died of ACC progression during follow-up with an overall survival of 5.4 months (0.5-39.3). Conclusions AA was able to control rapidly cortisol excess in most patients with a good safety profile. The results of this proof-of-concept study show that AA looks promising and may be viewed as an additional weapon to manage Cushing syndrome in patients with ACC. These findings pose the basis for power calculation and implementation of a prospective long-term study to establish AA efficacy in patients with a steroid-secreting ACC. Presentation: Sunday, June 12, 2022 11:00 a.m. - 11:15 a.m." @default.
• W4308133031 created "2022-11-08" @default.
• W4308133031 creator A5003133890 @default.
• W4308133031 creator A5003946700 @default.
• W4308133031 creator A5020684039 @default.
• W4308133031 creator A5023418111 @default.
• W4308133031 creator A5029272729 @default.
• W4308133031 creator A5038161482 @default.
• W4308133031 creator A5044446755 @default.
• W4308133031 creator A5048526224 @default.
• W4308133031 creator A5050426287 @default.
• W4308133031 creator A5053031594 @default.
• W4308133031 creator A5059703733 @default.
• W4308133031 creator A5072994077 @default.
• W4308133031 creator A5073568643 @default.
• W4308133031 creator A5086312742 @default.
• W4308133031 creator A5086533366 @default.
• W4308133031 date "2022-11-01" @default.
• W4308133031 modified "2023-09-26" @default.
• W4308133031 title "OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial." @default.
• W4308133031 doi "https://doi.org/10.1210/jendso/bvac150.171" @default.
• W4308133031 hasPublicationYear "2022" @default.
• W4308133031 type Work @default.
• W4308133031 citedByCount "0" @default.
• W4308133031 crossrefType "journal-article" @default.
• W4308133031 hasAuthorship W4308133031A5003133890 @default.
• W4308133031 hasAuthorship W4308133031A5003946700 @default.
• W4308133031 hasAuthorship W4308133031A5020684039 @default.
• W4308133031 hasAuthorship W4308133031A5023418111 @default.
• W4308133031 hasAuthorship W4308133031A5029272729 @default.
• W4308133031 hasAuthorship W4308133031A5038161482 @default.
• W4308133031 hasAuthorship W4308133031A5044446755 @default.
• W4308133031 hasAuthorship W4308133031A5048526224 @default.
• W4308133031 hasAuthorship W4308133031A5050426287 @default.
• W4308133031 hasAuthorship W4308133031A5053031594 @default.
• W4308133031 hasAuthorship W4308133031A5059703733 @default.
• W4308133031 hasAuthorship W4308133031A5072994077 @default.
• W4308133031 hasAuthorship W4308133031A5073568643 @default.
• W4308133031 hasAuthorship W4308133031A5086312742 @default.
• W4308133031 hasAuthorship W4308133031A5086533366 @default.
• W4308133031 hasBestOaLocation W43081330311 @default.
• W4308133031 hasConcept C121608353 @default.
• W4308133031 hasConcept C126322002 @default.
• W4308133031 hasConcept C126894567 @default.
• W4308133031 hasConcept C134018914 @default.
• W4308133031 hasConcept C168563851 @default.
• W4308133031 hasConcept C203092338 @default.
• W4308133031 hasConcept C2775832370 @default.
• W4308133031 hasConcept C2776735609 @default.
• W4308133031 hasConcept C2777899217 @default.
• W4308133031 hasConcept C2779384505 @default.
• W4308133031 hasConcept C2780192828 @default.
• W4308133031 hasConcept C2781399356 @default.
• W4308133031 hasConcept C71924100 @default.
• W4308133031 hasConcept C90924648 @default.
• W4308133031 hasConceptScore W4308133031C121608353 @default.
• W4308133031 hasConceptScore W4308133031C126322002 @default.
• W4308133031 hasConceptScore W4308133031C126894567 @default.
• W4308133031 hasConceptScore W4308133031C134018914 @default.
• W4308133031 hasConceptScore W4308133031C168563851 @default.
• W4308133031 hasConceptScore W4308133031C203092338 @default.
• W4308133031 hasConceptScore W4308133031C2775832370 @default.
• W4308133031 hasConceptScore W4308133031C2776735609 @default.
• W4308133031 hasConceptScore W4308133031C2777899217 @default.
• W4308133031 hasConceptScore W4308133031C2779384505 @default.
• W4308133031 hasConceptScore W4308133031C2780192828 @default.
• W4308133031 hasConceptScore W4308133031C2781399356 @default.
• W4308133031 hasConceptScore W4308133031C71924100 @default.
• W4308133031 hasConceptScore W4308133031C90924648 @default.
• W4308133031 hasIssue "Supplement_1" @default.
• W4308133031 hasLocation W43081330311 @default.
• W4308133031 hasLocation W43081330312 @default.
• W4308133031 hasOpenAccess W4308133031 @default.
• W4308133031 hasPrimaryLocation W43081330311 @default.
• W4308133031 hasRelatedWork W2046716996 @default.
• W4308133031 hasRelatedWork W2070619520 @default.
• W4308133031 hasRelatedWork W2094087834 @default.
• W4308133031 hasRelatedWork W2108405883 @default.
• W4308133031 hasRelatedWork W2559869616 @default.
• W4308133031 hasRelatedWork W2911632751 @default.
• W4308133031 hasRelatedWork W3169285313 @default.
• W4308133031 hasRelatedWork W3204635000 @default.
• W4308133031 hasRelatedWork W4282822450 @default.
• W4308133031 hasRelatedWork W2148508279 @default.
• W4308133031 hasVolume "6" @default.
• W4308133031 isParatext "false" @default.
• W4308133031 isRetracted "false" @default.
• W4308133031 workType "article" @default.